Anthony Mato MD, MSCEAssociate Professor
Matthew S. Davids MD, MMScAssociate Professor of Medicine
*Summarize the role of acalabrutinib in the management of chronic lymphocytic leukemia (CLL).
*Review recent clinical trial data regarding the use of acalabrutinib in the management of CLL.
*Describe novel and emerging clinical applications of acalabrutinib in managing CLL.
Acalabrutinib is an investigational agent for management of CLL that may be safe and efficacious in the long-term control of this disease. It is being investigated both as monotherapy and in combination with other agents. A Phase 3 program is underway, abstracts of which have been presented at the 2021 American Society of Hematology (ASH) annual meeting. Here, we learn from leading experts what the latest findings are related to this agent, how to interpret these findings, and what to expect soon.
The content for this program has been independently developed by Clinical Care Solutions.